Universe Pharmaceuticals INC (UPC) Income Statement
UPC FY2025 at a glance
Fiscal year ended September 30, 2025 · U.S. dollarsUPC revenue and net income
Where UPC's revenue goes
FY2025Each bar shows an amount and its share of revenue. UPC kept −20.6% of revenue as net income.
UPC profit margins
UPC growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −22.4% | −23.7% | −10.3% | — |
| Gross profit | +3.8% | −34.0% | −14.9% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
UPC quarterly EPS vs estimates
Universe Pharmaceuticals INC beat the analyst EPS estimate in 4 of the last 5 quarters.
UPC income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.9M | $23.0M | $32.3M | $40.1M | $48.0M | $30.7M | $33.2M | $28.5M |
| Cost of revenue | $11.6M | $17.0M | $22.0M | $18.3M | $22.7M | $16.6M | $19.8M | $15.1M |
| Gross profit | $6.3M | $6.1M | $10.3M | $21.9M | $25.3M | $14.1M | $13.4M | $13.4M |
| Research & development | $671,761 | $3.6M | $4.9M | $7.6M | $5.5M | $583,125 | $618,437 | $789,382 |
| Sales, general & admin | $8.0M | $9.9M | $9.0M | $21.3M | $6.3M | $2.8M | $2.3M | $2.4M |
| Total operating expenses | $9.2M | $31.0M | $13.8M | $28.9M | $11.7M | $3.7M | $3.4M | $3.6M |
| Operating income | −$2.9M | −$8.0M | −$3.5M | −$7.0M | $13.6M | $10.3M | $9.8M | $9.7M |
| Interest expense | $232,041 | $278,172 | $156,788 | $162,400 | $101,604 | $123,760 | $129,268 | $164,922 |
| Income before taxes | −$3.7M | −$8.1M | −$3.9M | −$8.0M | $13.6M | $10.1M | $9.7M | $9.5M |
| Income taxes | $606,704 | — | $2.3M | $752,419 | $2.4M | $2.5M | $2.1M | $1.9M |
| Net income | −$3.7M | −$8.7M | −$6.2M | −$8.7M | $11.3M | $7.6M | $7.6M | $7.6M |
| EBITDA | −$2.9M | −$7.4M | −$3.2M | −$6.4M | $14.2M | $10.6M | $10.2M | $10.1M |
| EPS (diluted) | −$6.52 | −$221.51 | — | — | — | $0.82 | $0.50 | $0.13 |
| Gross margin | 35.3% | 26.4% | 31.9% | 54.5% | 52.8% | 45.9% | 40.3% | 47.0% |
| Operating margin | −16.3% | −34.8% | −10.9% | −17.5% | 28.3% | 33.4% | 29.4% | 33.9% |
| Net margin | −20.6% | −37.9% | −19.1% | −21.8% | 23.6% | 24.6% | 22.7% | 26.7% |
| Jun '26 | Dec '25 | Mar '25 | Jun '24 | Dec '23 | Jun '23 | Dec '22 | Jun '22 | Mar '22 | Dec '21 | Mar '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M | $8.7M | $9.2M | $12.9M | $13.8M | $18.5M | $15.9M | $24.2M | $24.2M | $23.7M | $24.3M |
| Cost of revenue | $5.8M | $5.6M | $6.0M | $9.6M | $9.8M | $12.5M | $7.9M | $10.6M | $10.6M | $10.4M | $12.4M |
| Gross profit | $3.2M | $3.1M | $3.2M | $3.2M | $4.1M | $6.0M | $8.1M | $13.6M | $13.6M | $13.3M | $11.9M |
| Research & development | $86,443 | $574,925 | $96,836 | $86,503 | $2.6M | $2.3M | $7.5M | $134,460 | $134,460 | $5.0M | $320,545 |
| Sales, general & admin | — | — | $3.2M | — | — | — | $1.7M | $38.6M | — | $4.2M | $1.9M |
| Total operating expenses | $4.7M | $3.7M | $5.5M | $5.0M | $7.7M | $5.9M | $18.0M | $10.9M | $10.9M | $9.4M | $2.3M |
| Operating income | −$1.5M | −$589,158 | −$2.3M | −$1.7M | −$3.7M | $149,250 | −$10.1M | $2.7M | $2.7M | $4.0M | $9.6M |
| Interest expense | $126,156 | $103,296 | $128,745 | $136,613 | $82,219 | $74,569 | $74,011 | $88,389 | $88,389 | $54,933 | $46,671 |
| Income before taxes | −$1.6M | −$387,300 | −$3.3M | −$12.4M | −$4.1M | $258,931 | −$11.3M | $3.3M | $3.3M | $4.1M | $9.5M |
| Income taxes | — | — | −$58,444 | $665,148 | $1.3M | $974,358 | −$825,800 | $1.6M | $1.6M | −$52,221 | $2.4M |
| Net income | −$1.6M | −$387,300 | −$3.3M | −$13.1M | −$5.4M | −$715,427 | −$10.5M | $1.7M | $1.7M | $4.2M | $7.1M |
| EBITDA | −$1.3M | −$36,211 | −$2.9M | −$12.1M | −$3.8M | $591,277 | −$11.0M | $3.7M | $3.7M | $4.4M | $9.8M |
| EPS (diluted) | — | — | $0.00 | $0.00 | — | — | −$0.48 | $0.08 | — | $0.60 | — |
| Gross margin | 35.7% | 36.0% | 34.6% | 25.2% | 29.4% | 32.6% | 50.5% | 56.3% | 56.3% | 56.0% | 48.9% |
| Operating margin | −16.6% | −6.8% | −25.4% | −13.5% | −26.6% | 0.8% | −63.6% | 11.2% | 11.2% | 16.9% | 39.4% |
| Net margin | −17.2% | −4.4% | −35.9% | −101.7% | −39.4% | −3.9% | −65.7% | 7.2% | 7.2% | 17.6% | 29.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in UPC's financial statements (latest annual report filed January 29, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
UPC financial results
In fiscal year 2025 (ended September 30, 2025), Universe Pharmaceuticals INC reported revenue of $17.9 million, down 22.4% from the year before. It had a net loss of $3.7 million, a net profit margin of −20.6%. Diluted earnings per share came to −$6.52. Over five years revenue grew at an average rate of −10.3% a year.
See the UPC stock overview for the latest quote and news, or the UPC chart for price history and technical indicators.
UPC income statement FAQ
What is Universe Pharmaceuticals INC's annual revenue?
Universe Pharmaceuticals INC reported total revenue of $17.9 million for fiscal year 2025, which ended on September 30, 2025. That was down 22.4% from $23.0 million the previous year.
Is Universe Pharmaceuticals INC profitable?
No. Universe Pharmaceuticals INC reported a net loss of $3.7 million in fiscal 2025, a net profit margin of −20.6%; its operating margin was −16.3%.
What is Universe Pharmaceuticals INC's gross margin?
Universe Pharmaceuticals INC's gross margin was 35.3% in fiscal 2025: for every $100 of revenue, Universe Pharmaceuticals INC kept $35 after the direct cost of its products and services.
How much does Universe Pharmaceuticals INC spend on research and development?
Universe Pharmaceuticals INC spent $0.7 million on research and development in fiscal 2025, 3.8% of revenue.
How fast is Universe Pharmaceuticals INC growing?
Revenue grew −10.3% a year on average over the last five fiscal years, from $30.7 million to $17.9 million.
What are Universe Pharmaceuticals INC's earnings per share?
Universe Pharmaceuticals INC earned $-6.52 per diluted share in fiscal 2025, compared with $-221.51 a year earlier.
When does Universe Pharmaceuticals INC's fiscal year end?
Universe Pharmaceuticals INC's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on January 29, 2026.